Analysts forecast that Endo International plc (NASDAQ:ENDP) (TSE:ENL) will announce earnings per share (EPS) of $0.48 for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Endo International’s earnings, with estimates ranging from $0.44 to $0.51. Endo International reported earnings of $0.95 per share in the same quarter last year, which indicates a negative year over year growth rate of 49.5%. The business is expected to issue its next quarterly earnings report after the market closes on Thursday, May 6th.
According to Zacks, analysts expect that Endo International will report full year earnings of $2.12 per share for the current fiscal year, with EPS estimates ranging from $1.95 to $2.28. For the next financial year, analysts anticipate that the firm will post earnings of $2.11 per share, with EPS estimates ranging from $0.90 to $2.94. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, February 25th. The company reported $0.75 EPS for the quarter, topping the Zacks’ consensus estimate of $0.48 by $0.27. Endo International had a negative return on equity of 85.80% and a negative net margin of 5.30%. The business had revenue of $760.22 million for the quarter, compared to analyst estimates of $653.83 million. During the same period last year, the company posted $0.74 earnings per share.
Shares of Endo International stock traded down $0.38 during trading on Tuesday, reaching $5.49. 3,349,430 shares of the stock traded hands, compared to its average volume of 3,856,994. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -8.07 and a beta of 1.41. The business has a fifty day simple moving average of $6.89 and a two-hundred day simple moving average of $6.73. Endo International has a 52-week low of $2.71 and a 52-week high of $10.89.
In related news, Director Shane Cooke sold 17,290 shares of the company’s stock in a transaction dated Monday, March 15th. The shares were sold at an average price of $8.65, for a total transaction of $149,558.50. Following the completion of the transaction, the director now owns 97,104 shares in the company, valued at approximately $839,949.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.50% of the stock is owned by corporate insiders.
A number of hedge funds have recently added to or reduced their stakes in ENDP. Carolina Wealth Advisors LLC grew its stake in shares of Endo International by 109.5% in the 1st quarter. Carolina Wealth Advisors LLC now owns 8,894 shares of the company’s stock valued at $66,000 after buying an additional 4,648 shares during the period. Vantage Consulting Group Inc purchased a new position in shares of Endo International during the 4th quarter worth approximately $89,000. IFP Advisors Inc purchased a new position in shares of Endo International during the 4th quarter worth approximately $111,000. Nisa Investment Advisors LLC boosted its position in shares of Endo International by 131.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 17,700 shares of the company’s stock worth $127,000 after purchasing an additional 10,050 shares during the period. Finally, Everence Capital Management Inc. purchased a new position in shares of Endo International during the 1st quarter worth approximately $235,000. Institutional investors own 79.98% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.
Read More: What are different types of coverage ratios?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.